Surmodics Announces Successful Early Clinical Use of Pounce™ LP (Low Profile) Thrombectomy System, Designed to Address a Critical, Unmet Need by Facilitating Removal of Thrombi and Emboli Below the Knee
Surmodics to Participate in Upcoming Investor Conferences in August
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced the receipt of U.S. Food and Drug Administration (FDA) approval for the SurVeil™ drug-coated balloon (DCB).
It’s taken two years, but Surmodics has finally secured the long-awaited premarket approval from the FDA for its SurVeil drug-coated balloon.
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that management will participate in the Jefferies Healthcare Conference, which is being held in New York, NY, from June 7-9, 2023. Management will present on Thursday, June 8, at 1:30 p.m. ET (12:30 p.m. CT).
Surmodics Provides Regulatory Update on its Strategy to Submit an Amended Premarket Approval Application for the SurVeil™ Drug-Coated Balloon
As Surmodics is forced to delay the launch of its SurVeil drug-coated balloon by several months at least, erasing some expected earnings from its 2023 forecasts, the company is looking to cut costs in other areas.
Surmodics Provides Regulatory Update Related to its FDA Premarket Approval Application for the SurVeil™ Drug-Coated Balloon
Surmodics looks to pave a new path forward after the FDA sent a device submission back for revision yet again.
Surmodics Announces SWING Trial 12-Month Data to be Presented at ISET Conference on January 18